Cited by 154Nausea and vomiting managementPain Management and Opioid UsePalliative and Oncologic Care

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain.

Open access

Passik, Steven D., Lundberg, Jeremy, Kirsh, Kenneth L., Theobald, Dale, Donaghy, Kathleen, Holtsclaw, Elizabeth, Cooper, Maureen, Dugan, William·2002·Journal of Pain and Symptom Management

DOI 10.1016/s0885-3924(02)00391-3

Open this paper in CoChat — free account Open PDF

Abstract

This open-label pilot study explored the antiemetic activity of olanzapine, an atypical antipsychotic, in patients with advanced cancer requiring opioid analgesics for pain. Fifteen patients received 2 days of a washout and placebo "run-in" followed by two day periods on each of three doses of olanzapine (2.5 mgs, 5 mgs, and 10 mgs). Patients completed a daily food journal as well as the Mini Mental State Exam, Simpson Angus Scale, Barnes Akathisia Scale, and the Functional Assessment of Cancer Therapy-General across four time periods, with special attention being placed on the nausea item. Eleven women and 4 men with varied primary cancer sites participated. The average age of the sample was 58 years (SD = 16.8). All three dose levels were associated with significant reductions in nausea compared to baseline. Diary entries recorded by the subjects suggested substantial benefits to overall well being and the 5mg condition was associated with statistically significant improvement in overall quality of life over baseline (F = 12.0, p < 0.005). No extrapyramidal symptoms were noted and mental status exams were not changed over the course of the eight days. These results suggest an antiemetic effect for olanzapine and indicate the need for a controlled trial.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0885-3924(02)00391-3

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
Tol, H. H. M. V., Bunzow, J. R., Guan, H., Sunahara, R. K., Seeman, P. M., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,015
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,352
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Gompel, P. V., Lesage, A. S., Loore, K. D., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1
Sunahara, R. K., Guan, H., O’Dowd, B. F., Seeman, P. M., Laurier, L. G., Ng, G., George, S. R., Torchia, J., Tol, H. H. M. V., & Niznik, H. B. (1991) · Nature · doi:10.1038/350614a0 · Cited by 1,166
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P. M., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,061
Dopamine receptor pharmacology
Seeman, P. M., & Tol, H. H. M. V. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90323-9 · Cited by 969
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G. D., Tran, P., SATTERLEE, W. G., Sanger, T. M., & Hamilton, S. H. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 777
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors
Choudhary, M. S., Craigo, S. C., Sibley, D. R., Roth, B. L., Monsma, F. J., Shen, Y., Uluer, A., & Meltzer, H. Y. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/74zp-ze10 · Cited by 592

Show all 23 references

Sorted by citations

Olanzapine for the prevention of chemotherapy-induced nausea and vomiting.
Navari, R. M., Qin, R., Ruddy, K. J., Liu, H., Powell, S. F., Bajaj, M., Dietrich, L., Biggs, D., Lafky, J. M., & Loprinzi, C. L. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515725 · Cited by 452
Opioid induced nausea and vomiting
Smith, H. S., & Laufer, A. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.074 · Cited by 225
Ralstonia eutropha Strain H16 as Model Organism for PHA Metabolism and for Biotechnological Production of Technically Interesting Biopolymers
Reinecke, F., & Steinbüchel, A. (2008) · Microbial Physiology · doi:10.1159/000142897 · Cited by 229
Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review
Jordan, K., Jahn, F., & Aapro, M. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv138 · Cited by 203
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
Tan, L., Liu, J., Liu, X., Chen, J., Yan, Z., Yang, H., & Zhang, D. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-131 · Cited by 199
Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea
Sharma, R., Tobin, P. J., & Clarke, S. J. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)01735-3 · Cited by 198
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
Navari, R. M., Nagy, C. K., & Gray, S. E. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-012-1710-6 · Cited by 181
Treating nausea and vomiting in palliative care: a review
Glare, P. A., Miller, J., Николова, & Tickoo (2011) · Clinical Interventions in Aging · doi:10.2147/cia.s13109 · Cited by 170
Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer
Glare, P. A., Pereira, G., Kristjanson, L. J., Tattersall, M., & Stockler, M. R. (2004) · Supportive Care in Cancer · doi:10.1007/s00520-004-0629-y · Cited by 157
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study
Navari, R. M., Einhorn, L. H., Passik, S. D., Loehrer, P. J., Johnson, C. S., Mayer, M. L., McClean, J., Vinson, J., & Pletcher, W. (2005) · Supportive Care in Cancer · doi:10.1007/s00520-004-0755-6 · Cited by 146
Self-citation
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study
Mizukami, N., Yamauchi, M., Koike, K., Watanabe, A., Ichihara, K., Masumori, N., & Yamakage, M. (2013) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2013.05.003 · Cited by 116
Management of Intractable Nausea and Vomiting in Patients at the End of Life
Wood, G., Shega, J. W., Lynch, B., & Roenn, J. H. V. (2007) · JAMA · doi:10.1001/jama.298.10.1196 · Cited by 111
Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer.
Srivastava, M., Brito-Dellan, N., Davis, M. P., Leach, M., & Lagman, R. (2003) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(03)00143-x · Cited by 106
A Systematic Review of the Treatment of Nausea and/or Vomiting in Cancer Unrelated to Chemotherapy or Radiation
Davis, M. P., & Hallerberg, G. A. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.08.010 · Cited by 105
A Phase I Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients: A Hoosier Oncology Group Study
Passik, S. D., Navari, R. M., Jung, S., Nagy, C. K., Vinson, J., Kirsh, K. L., & Loehrer, P. J. (2004) · Cancer Investigation · doi:10.1081/cnv-200029066 · Cited by 102
Self-citation
Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects
Kast, R. E., & Foley, K. F. (2007) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2006.00760.x · Cited by 102
Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial.
Navari, R. M., & Brenner, M. C. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-009-0739-7 · Cited by 99
Comparative activity of antiemetic drugs
Jordan, K., Schmoll, H., & Aapro, M. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.08.003 · Cited by 95
Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis
Chiu, L., Chow, R., Popovic, M. M., Navari, R. M., Shumway, N. M., Chiu, N., Lam, H., Milakovic, M., Pasetka, M., Vuong, S., et al. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3075-8 · Cited by 92
The muscarinic system, cognition and schizophrenia
Carruthers, S. P., Gurvich, C. T., & Rossell, S. L. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.011 · Cited by 90
Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting
Navari, R. M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.08.048 · Cited by 87
Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial
Navari, R. M., Pywell, C. M., Le-Rademacher, J. G., White, P., Dodge, A. B., Albany, C., & Loprinzi, C. L. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1052 · Cited by 78
Olanzapine for intractable nausea in palliative care patients.
Jackson, W. C., & Tavernier, L. (2003) · Journal of Palliative Medicine · doi:10.1089/109662103764978506 · Cited by 78
The pathophysiology, incidence, impact, and treatment of opioid‐induced nausea and vomiting
Mallick‐Searle, T., & Fillman, M. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12532 · Cited by 73
Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
Navari, R. M. (2015) · BioMed Research International · doi:10.1155/2015/595894 · Cited by 70
Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations
Laugsand, E. A., Kaasa, S., & Klepstad, P. (2011) · Palliative Medicine · doi:10.1177/0269216311404273 · Cited by 70
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial
Abé, M., Hirashima, Y., Kasamatsu, Y., Kado, N., Komeda, S., Kuji, S., Tanaka, A., Takahashi, N., Takekuma, M., Hihara, H., et al. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2829-z · Cited by 69
Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis
Yoodee, J., Permsuwan, U., & Nimworapan, M. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.017 · Cited by 65
Atypical Antipsychotic Quetiapine in the Management of Severe Refractory Functional Gastrointestinal Disorders
Grover, M., Dorn, S. D., Weinland, S. R., Dalton, C. B., Gaynes, B. N., & Drossman, D. A. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0723-6 · Cited by 63
Treatment of Nausea and Vomiting in Terminally Ill Cancer Patients
Glare, P. A., Dunwoodie, D., Clark, K., Ward, A., Yates, P. M., Ryan, S., & Hardy, J. R. (2008) · Drugs · doi:10.2165/0003495-200868180-00004 · Cited by 61
Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction.
Kaneishi, K., Kawabata, M., & Morita, T. (2012) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2011.10.023 · Cited by 58
A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients.
Passik, S. D., Kirsh, K. L., Theobald, D. E., Dickerson, P., Trowbridge, R., Gray, D., Beaver, M., Comparet, J., & Brown, J. (2003) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(03)00078-2 · Cited by 56
Self-citation
Nausea and vomiting in advanced cancer
Gordon, P., LeGrand, S. B., & Walsh, D. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.10.010 · Cited by 52
Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review
Chow, R., Chiu, L., Navari, R. M., Passik, S. D., Chiu, N., Popovic, M. M., Lam, H., Pasetka, M., Chow, E., & DeAngelis, C. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-3000-6 · Cited by 51
Self-citation
Prevention of Emesis from Multiple-Day and High-Dose Chemotherapy Regimens
Navari, R. M. (2007) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2007.0007 · Cited by 51
Centrally Acting Therapies for Irritable Bowel Syndrome
Grover, M., & Drossman, D. A. (2011) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2010.12.003 · Cited by 52
Nausea and Vomiting in Advanced Cancer
Navari, R. M. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0704-8 · Cited by 49
Antiemesis
Ettinger, D. S., Armstrong, D. K., Barbour, S. Y., Berger, M. J., Bierman, P. J., Bradbury, B., Ellis, G. K., Kirkegaard, S., Kloth, D. D., Kris, M. G., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0047 · Cited by 48
Low-dose levomepromazine in refractory emesis in advanced cancer patients: an open-label study
Eisenchlas, J. H., Garrigue, N., Junin, M., & Simone, G. G. D. (2005) · Palliative Medicine · doi:10.1191/0269216305pm972oa · Cited by 47
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial
Bajpai, J., Kapu, V., Rath, S., Kumar, S., Sekar, A., Patil, P., Siddiqui, A., Srikanth, A., Pawar, A., Srinivas, S., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00628-9 · Cited by 46
The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India
Babu, G., Saldanha, S., Chinnagiriyappa, L. K., Jacob, L. A., Mallekavu, S. B., Dasappa, L., Kiran, P. R., Sreevatsa, A., Appachu, S., Unnikrishnan, V., et al. (2016) · Chemotherapy Research and Practice · doi:10.1155/2016/3439707 · Cited by 46
Safety and efficacy of commonly used antiemetics
Hendren, G., Aponte-Feliciano, A., & Kovac, A. L. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1080688 · Cited by 44
Psychotropic agents in functional gastrointestinal disorders
Grover, M., & DROSSMAN, D. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.012 · Cited by 42
Nausea and Vomiting in Advanced Cancer
Ang, S. K., Shoemaker, L. K., & Davis, M. P. (2010) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909110361228 · Cited by 42
Nausea and Vomiting: a Palliative Care Imperative
Wickham, R. J. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0871-6 · Cited by 40
Updates in Cancer Cachexia: Clinical Management and Pharmacologic Interventions
Pandey, S., Bradley, L., & Fabbro, E. D. (2024) · Cancers · doi:10.3390/cancers16091696 · Cited by 42
Olanzapine: An Antiemetic Option for Chemotherapy-Induced Nausea and Vomiting
Brafford, M. V., & Glode, A. E. (2014) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2014.5.1.8 · Cited by 40
Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to Chemotherapeutic Agents
Sanomachi, T., Suzuki, S., Kuramoto, K., TAKEDA, H., Sakaki, H., Togashi, K., Seino, S., Yoshioka, T., Okada, M., & Kitanaka, C. (2017) · Anticancer Research · doi:10.21873/anticanres.12067 · Cited by 40
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature
Chow, R., Herrstedt, J., Aapro, M., Chiu, L., Lam, H., Prsic, E. H., Lock, M. I., DeAngelis, C., & Navari, R. M. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-020-05935-7 · Cited by 40
MASCC antiemetics in advanced cancer updated guideline
Davis, M. P., Hui, D., Davies, A. N., Ripamonti, C. I., Capela, A., DeFeo, G., Fabbro, E. D., & Bruera, E. D. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06437-w · Cited by 40
Opioid Side Effects and Their Treatment in Patients with Chronic Cancer and Noncancer Pain
McNicol, E. D. (2008) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360280802537225 · Cited by 40
Olanzapine
Prommer, E. (2012) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909112441241 · Cited by 41
Usefulness of Olanzapine as an Adjunct to Opioid Treatment and for the Treatment of Neuropathic Pain
Torigoe, K., Nakahara, K., Rahmadi, M., Yoshizawa, K., Horiuchi, H., Hirayama, S., Imai, S., Kuzumaki, N., Itoh, T., Yamashita, A., et al. (2011) · Anesthesiology · doi:10.1097/aln.0b013e31823c7e56 · Cited by 39
Olanzapine for treatment and prevention of acute chemotherapy‐induced vomiting in children: A retrospective, multi‐center review
Flank, J., Thackray, J., Nielson, D., August, A., Schechter, T., Alexander, S. W., Sung, L., & Dupuis, L. L. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25286 · Cited by 37
A Retrospective Chart Review of the Antiemetic Effectiveness of Risperidone in Refractory Opioid-Induced Nausea and Vomiting in Advanced Cancer Patients
Okamoto, Y., Tsuneto, S., Matsuda, Y., Inoue, T., Tanimukai, H., Tazumi, K., Ono, Y., Kurokawa, N., & Uejima, E. (2007) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2006.10.020 · Cited by 37
Special considerations in the treatment of patients with bipolar disorder and medical co-morbidities
McLaren, K., & Marangell, L. B. (2004) · Annals of General Hospital Psychiatry · doi:10.1186/1475-2832-3-7 · Cited by 36
Olanzapine in the management of difficult to control nausea and vomiting in a palliative care population: a case series.
MacKintosh, D. (2016) · Journal of Palliative Medicine · doi:10.1089/jpm.2015.0224 · Cited by 33
Novel N-indolylmethyl substituted olanzapine derivatives: their design, synthesis and evaluation as PDE4B inhibitors
Gorja, D. R., Mukherjee, S., Meda, C. L. T., Deora, G. S., Kumar, K. L., Jain, A., Chaudhari, G. H., Chennubhotla, K. S., Banote, R. K., Kulkarni, P., et al. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob27424a · Cited by 33
A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients
Fonte, C., Fatigoni, S., & Roila, F. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.02.010 · Cited by 32
The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature
Saudemont, G., Prod’Homme, C., Silva, A. D., Villet, S., Reich, M., Penel, N., & Gamblin, V. (2020) · BMC Palliative Care · doi:10.1186/s12904-020-00559-4 · Cited by 32
Optimizing Emetic Control in Children Receiving Antineoplastic Therapy
Dupuis, L. L., & Nathan, P. C. (2009) · Pediatric Drugs · doi:10.2165/11316190-000000000-00000 · Cited by 31
Perioperative management of the chronic pain patient
Köpf, A., Banzhaf, A., & Stein, C. (2004) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2004.08.002 · Cited by 31
Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis
Zhang, Z., Zhang, Y., Chen, G., Hong, S., Yang, Y., Fang, W., Luo, F., Chen, X., Ma, Y., Zhao, Y., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0378 · Cited by 31
Emerging drugs for chemotherapy-induced emesis
Navari, R. M., & Province, P. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.1.137 · Cited by 31
A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting
Wang, X., Feng, Y., Chen, Y., Gao, B. L., & Han, B. (2014) · Scientific Reports · doi:10.1038/srep04813 · Cited by 30
Psychopharmacologic and Behavioral Treatments for Functional Gastrointestinal Disorders
Grover, M., & Drossman, D. A. (2009) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2008.12.001 · Cited by 30
Cancer and chemotherapy-induced nausea and vomiting
Bosnjak, S. M., Dimitrijević, J., & Djordjevic, F. (2016) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000206 · Cited by 30
Nausea and vomiting in palliative care
Collis, E., & Mather, H. L. (2015) · BMJ · doi:10.1136/bmj.h6249 · Cited by 29
Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity
Vig, S. J., Seibert, L., & Green, M. R. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1540-z · Cited by 29
Opioids and GI Motility—Friend or Foe?
Lee, A. A., & Hasler, W. L. (2016) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-016-0112-0 · Cited by 28
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Navari, R. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-27016-6_6 · Cited by 28
The atypical antipsychotic, olanzapine, potentiates ghrelin-induced receptor signaling: An in vitro study with cells expressing cloned human growth hormone secretagogue receptor
Tagami, K., Kashiwase, Y., Yokoyama, A., Nishimura, H., Miyano, K., Suzuki, M., Shiraishi, S., Matoba, M., Ohe, Y., & Uezono, Y. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.12.010 · Cited by 27
Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis
Chelkeba, L., Gidey, K., Mamo, A., Yohannes, B., Matso, T., & Melaku, T. (2017) · Pharmacy Practice · doi:10.18549/pharmpract.2017.01.877 · Cited by 27
Olanzapine for Intractable Nausea and Vomiting in Palliative Care Patients Not Receiving Chemotherapy
Atkinson, S. R. (2014) · Journal of Palliative Medicine · doi:10.1089/jpm.2014.0030 · Cited by 26
Clinical Guidelines for Management of Gastrointestinal Symptoms in Cancer Patients: The Japanese Society of Palliative Medicine Recommendations
Hisanaga, T., Shinjo, T., Imai, K., Katayama, K., Kaneishi, K., Honma, H., Takagaki, N., Osaka, I., Matsuo, N., Kohara, H., et al. (2019) · Journal of Palliative Medicine · doi:10.1089/jpm.2018.0595 · Cited by 26
Olanzapine-induced delirium in a terminally ill cancer patient
Morita, T., Tei, Y., Shishido, H., & Inoue, S. (2004) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2004.04.008 · Cited by 26
QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist
Liu, J., Tan, L., Zhang, H., Li, H., Liu, X., Yan, Z., Chen, J., Yang, H., & Zhang, D. (2014) · European Journal of Cancer Care · doi:10.1111/ecc.12260 · Cited by 24
Olanzapine and Betamethasone Are Effective for the Treatment of Nausea and Vomiting due to Metastatic Brain Tumors of Rectal Cancer
Suzuki, M., Komuro, K., & Ohara, K. (2014) · Case Reports in Gastroenterology · doi:10.1159/000358044 · Cited by 24
Low-dose of olanzapine has ameliorating effects on cancer-related anorexia
Okamoto, H., Shono, K., & Nozaki‐Taguchi, N. (2019) · Cancer Management and Research · doi:10.2147/cmar.s191330 · Cited by 24
A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting
Sato, J., Tanaka, R., Ishikawa, H., Suzuki, T., & Shino, M. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-019-04884-0 · Cited by 24
Olanzapine for nausea and vomiting.
Licup, N., & Baumrucker, S. (2010) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909110369532 · Cited by 23
The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
Vimolchalao, V., Sakdejayont, S., Wongchanapai, P., Sukprakun, S., Angspatt, P., Thawinwisan, W., Chenaksara, P., Sriuranpong, V., Vinayanuwatikun, C., Parinyanitikun, N., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01570-3 · Cited by 23
Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer
Wang, W., Lou, G., & Zhang, Y. (2018) · Medicine · doi:10.1097/md.0000000000012331 · Cited by 21
Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy‐Induced Nausea and Vomiting
DeRemer, D. L., Clemmons, A. B., Orr, J., Clark, S. M., & Gandhi, A. S. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1703 · Cited by 20
Use of olanzapine for the relief of nausea and vomiting in patients with advanced cancer: a multicenter survey in Japan
Kaneishi, K., Nishimura, K., Sakurai, N., Imai, K., Matsuo, N., Takahashi, N., Okamoto, K., Suga, A., Sano, H., Maeda, I., et al. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3101-x · Cited by 18
Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study.
Harder, S., Groenvold, M., Isaksen, J., Sigaard, J., Frandsen, K. B., Neergaard, M. A., Mondrup, L., & Herrstedt, J. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-018-4593-3 · Cited by 17
Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy
Abé, M., Kasamatsu, Y., Kado, N., Kuji, S., Tanaka, A., Takahashi, N., Takekuma, M., & Hirashima, Y. (2015) · BioMed Research International · doi:10.1155/2015/956785 · Cited by 17
Anesthesia and Treatment of Chronic Pain
Stein, C., & Köpf, A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06959-8.00058-3 · Cited by 17
Behandlung von Übelkeit und Erbrechen mit Prokinetika und Neuroleptika bei Palliativpatienten
Benze, G., Alt‐Epping, B., Geyer, A., & Nauck, F. (2012) · Der Schmerz · doi:10.1007/s00482-012-1216-7 · Cited by 17
Controlling emesis: evolving challenges, novel strategies.
Nevidjon, B., & Chaudhary, R. T. (2010) · PubMed · Cited by 16
Prioritising drugs for single patient (n-of-1) trials in palliative care
Nikles, J., Mitchell, G. K., Walters, J., Hardy, J. R., Good, P. D., Rowett, D. S., Shelby‐James, T., & Currow, D. C. (2009) · Palliative Medicine · doi:10.1177/0269216309106461 · Cited by 14
Low-Dose Olanzapine, Sedation and Chemotherapy-Induced Nausea and Vomiting: A Prospective Randomized Controlled Study
Mukhopadhyay, S., Dutta, P., Banerjee, S., Bhattacharya, B., Biswas, S., & Navari, R. M. (2021) · Future Oncology · doi:10.2217/fon-2020-0834 · Cited by 13
The Management of Nausea and Vomiting Not Related to Anticancer Therapy in Patients with Cancer
Hardy, J. R., & Davis, M. P. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00813-0 · Cited by 12
Palliation of nausea and vomiting
Hardy, J. R., Glare, P. A., Yates, P. M., & Mannix, K. A. (2015) · doi:10.1093/med/9780199656097.003.0202 · Cited by 12
Should Olanzapine be Advocated Over Conventional Anti-Emetics for the Prevention of Chemotherapy-Induced Nausea and Vomiting? An Updated Meta-Analysis of Randomized Control Trials
Bahbah, E. I., Abdalla, A. R., Abdelshafy, K., Almohandes, A. D., Menshawy, A., Aziz, M. A. E., Ebada, M. A., Hegab, A. M., & Negida, A. (2019) · Current Enzyme Inhibition · doi:10.2174/1573408015666190620165507 · Cited by 11
Effects of Low-Dose Olanzapine on Duloxetine-Related Nausea and Vomiting for the Treatment of Major Depressive Disorder
Zhong, Z., Zhang, Y., Han, H., Huang, Z., Wang, J., Chen, M., & Zhang, J. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000167 · Cited by 10
Olanzapine in the Treatment of Refractory Nausea and Vomiting: A Case Report and Review of the Literature
Langley-DeGroot, M., JOSEPH, D. R., Hirst, J. M., & Roeland, E. J. (2015) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.3109/15360288.2015.1035831 · Cited by 9
A phase II study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients
Nishimura, J., Hasegawa, A., Kudo, T., Otsuka, T., Yasui, M., Matsuda, C., Haraguchi, N., Ushigome, H., Nakai, N., Abe, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84225-6 · Cited by 8
Olanzapine for Preventing Nausea and Vomiting Induced by Moderately and Highly Emetogenic Chemotherapy
Wang, S.-Y., Yang, Z., & Zhang, L. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.22.9587 · Cited by 8
Oral olanzapine versus oral ondansetron for prevention of post-operative nausea and vomiting. A randomized, controlled study
Ibrahim, M., Eldesuky, H. I., & Ibrahim, T. H. (2013) · Egyptian Journal of Anaesthesia · doi:10.1016/j.egja.2013.01.002 · Cited by 8

Authors: Passik, S. D., Lundberg, J., Kirsh, K. L., Theobald, D., Donaghy, K., Holtsclaw, E., Cooper, M., & Dugan, W.
Affiliations: Markey Cancer Center (US)
Corresponding author: Passik, Steven D.
Venue: Journal of Pain and Symptom Management
Publisher: Elsevier BV
Published: 2002-06
Volume: 23
Issue: 6
Pages: 526-532
ISSN: 0885-3924 (ISSN-L)
DOI: 10.1016/s0885-3924(02)00391-3
OpenAlex: W2027393266
Semantic Scholar: f9eaa050229fb9860cecff4f581d7d4274d6af00
Cited by: 154
References: 23
Citations by year: 2026: 2 · 2025: 2 · 2024: 5 · 2023: 3 · 2022: 2 · 2021: 9 · 2020: 6 · 2019: 6 · 2018: 6 · 2017: 6 · 2016: 10 · 2015: 17 · 2014: 8 · 2013: 9 · 2012: 10
FWCI: 3.81
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 6435 d)
Locations: Journal of Pain and Symptom Management (publishedVersion)
PubMed (publishedVersion)
Funders: Eli Lilly and Company
Topics: Health Sciences › Medicine › Surgery › Nausea and vomiting management
Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Palliative and Oncologic Care
Keywords: olanzapine, antiemetic activity, nausea, advanced cancer, cancer pain, opioid analgesics, atypical antipsychotics, quality of life, extrapyramidal symptoms, akathisia, functional status
MeSH terms: Olanzapine, Adolescent, Adult, Aged, Aged, 80 and over, Antiemetics, Benzodiazepines, Dyskinesia, Drug-Induced, Female, Humans, Male, Middle Aged, Nausea, Neoplasms, Pain, Palliative Care, Pilot Projects, Pirenzepine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks